摘要
Summary What is already known on this topic?The global burden of chronic obstructive pulmonary disease(COPD)is serious.Pneumococcal infection is associated with acute exacerbations of COPD(AECOPD).The 23-valent pneumococcal polysaccharide vaccine(PPSV23)is recommended for COPD patients to decrease AECOPD due to pneumococcus,but evidence on the immunogenicity of PPSV23 in COPD patients is limited.What is added by this report?
基金
National Key R&D Program of China(2017YFC1309304).
